SUMMIT, N.J., Oct. 11, 2023 /PRNewswire/ -- CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from three studies supporting the clinical, public health and economic value of both cell-based and adjuvanted seasonal influenza vaccines. The data highlights the effectiveness and value of influenza vaccination in the U.S. across all relevant age groups, risk profiles, and influenza seasons with different levels of influenza burden.1,2,3 These analyses will be presented during poster sessions this week at the IDWeek 2023 conference taking place in Boston, Mass. from October 11-15, 2023.
Read more at prnewswire.comNew Data Presented at IDWeek 2023 Demonstrates Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
